vspВопросы современной педиатрииCurrent Pediatrics1682-55271682-5535Издательство «ПедиатрЪ»10.15690/vsp.v14i2.1290vsp-62Research ArticleОБЗОРЫ ЛИТЕРАТУРЫLITERATURE REVIEWВНУТРИВЕННЫЙ ИММУНОГЛОБУЛИН В ДЕТСКОЙ РЕВМАТОЛОГИЧЕСКОЙ ПРАКТИКЕINTRAVENOUS IMMUNOGLOBULIN IN PEDIATRIC RHEUMATOLOGY PRACTICEАлексееваЕ. И.AlexeevaE. I.

доктор медицинских наук, профессор, заведующая ревматологическим отделением НЦЗД, декан педиатрического факультета Первого МГМУ им. И.М. Сеченова Адрес: 119991, Москва, Ломоносовский проспект, д. 2, стр. 1, тел.: +7 (499) 134-02-97

alekatya@ya.ruДенисоваР. В.DenisovaR. V.alekatya@ya.ruЧомахидзеА. М.ChomakhidzeA. M.alekatya@ya.ruНаучный центр здоровья детей, Москва, Российская Федерация Первый Московский государственный медицинский университет им. И.М. Сеченова, Российская ФедерацияРоссияScientific Centre of Children’s Health, Moscow, Russian Federation I.M. Sechenov First Moscow State Medical University, Russian FederationRussian FederationНаучный центр здоровья детей, Москва, Российская ФедерацияРоссияScientific Centre of Children’s Health, Moscow, Russian FederationRussian Federation201517042015142Вопросы современной педиатрии219223Copyright © Алексеева Е.И., Денисова Р.В., Чомахидзе А.М., 20152015Алексеева Е.И., Денисова Р.В., Чомахидзе А.М.Alexeeva E.I., Denisova R.V., Chomakhidze A.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vsp.spr-journal.ru/jour/article/view/62

Современное успешное лечение ревматических болезней невозможно без применения внутривенного иммуноглобулина. Использование внутривенного иммуноглобулина основано на строгих показаниях, разработанных в результате длительных многоцентровых контролируемых исследований. В статье освещены вопросы применения иммуноглобулина в детской ревматологической практике, представлен обзор литературы с результатами оценки эффективности применения внутривенного иммуноглобулина, подтверждающий эффективность препарата лишь при некоторых ревматических заболеваниях.

 

Modern successful treatment of rheumatic diseases is impossible without the use of intravenous immunoglobulin. The use of intravenous immunoglobulin is based on strict indications developed as a result of long-term multicenter controlled studies. The article highlights the issues of using immunoglobulin in pediatric rheumatology practice, and provides the review of literature with the results from the evaluation of the efficiency of intravenous immunoglobulin confirming the efficiency of the drug only for certain rheumatic diseases.

 

детивнутривенный иммуноглобулинревматические заболеванияchildrenintravenous immunoglobulinrheumatic diseasesReferencesCohn E. J. et al. The history of plasma fractionation. Advances in Military Medicine ed. E. C. Andrus. Boston. 1948; 1: 364–443.Cohn E.J. et al. The history of plasma fractionation. Advances in Military Medicine ed. E.C. Andrus. Boston. 1948; 1: 364–443.Bruton O. Agammaglobulinemia. Pediatrics. 1952; 9: 722–728.Bruton O. Agammaglobulinemia. Pediatrics. 1952; 9: 722–728.Aseeva E.A., Solov'ev S.K. Prospects for the use of intravenous immunoglobulin in autoimmune rheumatic diseases. Sovremennaya revmatologiya = Current rheumatology. 2014;1:45−52.Aseeva E.A., Solov'ev S.K. Prospects for the use of intravenous immunoglobulin in autoimmune rheumatic diseases. Sovremennaya revmatologiya = Current rheumatology. 2014; 1: 45−52.Schultze H. E., Schwik G. On new possibilities of intravenous gamma globulin administration. Dtsch Med Wochenschr. 1962; 24 (87): 1643–1644.Schultze H.E., Schwik G. On new possibilities of intravenous gamma globulin administration. Dtsch Med Wochenschr.1962; 24 (87): 1643−1644.Kondratenko I.V., Zaplatnikov A.L., Bologov A.A. Intravenous immunoglobulins. What and when. Detskaya bol'nitsa = Children's hospital. 2010;4:50−60.Kondratenko I.V., Zaplatnikov A.L., Bologov A.A. Intravenous immunoglobulins. What and when. Detskaya bol'nitsa = Children's hospital. 2010; 4: 50−60.Kazatchkine M., Kaveri S. Immunomodulation of autoimmune and inflammatory diseases witch intravenous immune giobulin.Kazatchkine M., Kaveri S. Immunomodulation of autoimmune and inflammatory diseases witch intravenous immune giobulin. N. Engl. J. Med. 2001; 34: 747−755.N. Engl. J. Med. 2001; 34: 747–755.Averchenkov V.M., Palagin I.S. Intravenous immunoglobulin: mechanism of action and clinical applications. Klinicheskaya mikrobiologicheskaya i antimikrobnaya khimioterapiya = Clinical microbiology and antimicrobial chemotherapy. 2004; 6 (3): 273−281.Averchenkov V.M., Palagin I.S. Intravenous immunoglobulin: mechanism of action and clinical applications. Klinicheskaya mikrobiologicheskaya i antimikrobnaya khimioterapiya = Clinical microbiology and antimicrobial chemotherapy. 2004;6(3):273−281.Negi V.-S., Elluru S., Siberil S. et al. Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J. Clin. Immun. 2007; 27 (3): 233−245.Negi V.-S., Elluru S., Siberil S. et al. Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J. Clin. Immun. 2007; 27 (3): 233–245.Fridmann W. Regulation of B-cell activation and antigen presentation by Fc-receptors. Curr. Opin. Immunol. 1993; 340 (3): 355−360.Fridmann W. Regulation of B-cell activation and antigen presentation by Fc-receptors. Curr. Opin. Immunol. 1993; 340 (3): 355–360.Yu Z., Lennon V. Mechanism of intravenous immunoglobuline therapy in antibody-mediated autoimmune diseases. N. Engl. J. Med. 1999; 340 (3): 227−228.Yu Z., Lennon V. Mechanism of intravenous immunoglobuline therapy in antibody-mediated autoimmune diseases. N. Engl. J. Med. 1999; 340 (3): 227–228.Bleeker W., Teeling J., Hack C. Accelerated autoantibody clearance by intravenous immunoglobulin therapy experimental models of determine the magnitude and time course of the effect. Blood. 2001; 98 (10): 3136−3142.Bleeker W., Teeling J., Hack C. Accelerated autoantibody clearance by intravenous immunoglobulin therapy experimental models of determine the magnitude and time course of the effect. Blood. 2001; 98 (10): 3136–3142.Mollnes T., Hogasen K., Hoass B. et al. Inhibition of complement-mediated red cells lysis by immunoglobulins is depended on the ig isitype and its C1 binding proteins. Scand. J. Immunol. 1995; 41 (5): 449−456.Mollnes T., Hogasen K., Hoass B. et al. Inhibition of complement-mediated red cells lysis by immunoglobulins is depended on the ig isitype and its C1 binding proteins. Scand. J. Immunol. 1995; 41 (5): 449–456.Prasad N., Papoff G., Zeuner A. et al. Therapeutic preparations of normal polyspecific IgG (IVIg) induse apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IV Ig involving the Fas apoptosic pathway. J. Immunol. 1998; 161: 3781−3790.Prasad N., Papoff G., Zeuner A. et al. Therapeutic preparations of normal polyspecific IgG (IVIg) induse apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IV Ig involving the Fas apoptosic pathway. J. Immunol. 1998; 161: 3781–3790.Averchenkov V.M., Palagin I.S. Intravenous immunoglobulin: mechanism of action and clinical applications. Klinicheskaya mikrobiologicheskaya i antimikrobnaya khimioterapiya = Clinical microbiology and antimicrobial chemotherapy. 2004; 6 (3): 273−281.Alexeeva E.I., Isaeva K.B., Shakhbazyan I.E., Zholobova E.S. The effectiveness of intravenous immunoglobulin treatment of patients with systemic type of juvenile rheumatoid arthritis. Klinicheskaya meditsina = Clinical medicine. 2001;2:30−33.Alekseeva E.I., Isaeva K.B., Shakhbazyan I.E., Zholobova E.S. The effectiveness of intravenous immunoglobulin treatment of patients with systemic type of juvenile rheumatoid arthritis. Klinicheskaya meditsina = Clinical medicine. 2001; 2: 30−33.AI-Mayouf S. M. et al. Intravenous immunoglobulin therapy for juvenile dermatomyositis: efficacy and safety. J. Rheumatol. 2000; 27: 2498–2503.AI-Mayouf S.M. et al. Intravenous immunoglobulin therapy for juvenile dermatomyositis: efficacy and safety. J. Rheumatol. 2000; 27: 2498−2503.Ballow M., Park A. The uses of intravenous immune globulin in collagen vascular disoders. J. Allergy Clin. Immunol. 1989; 84 (4 Pt. 2): 608–612.Ballow M., Park A. The uses of intravenous immune globulin in collagen vascular disoders. J. Allergy Clin. Immunol. 1989; 84 (4 Pt. 2): 608−612.Jayne D. R., Chapel H., Adu D. et al. Intravenous immunoglobuline for ANCA-associated systemic vasculitis with persistant disease activity. QJM. 2009; 93 (7): 433–439.Jayne D.R., Chapel H., Adu D. et al. Intravenous immunoglobuline for ANCA-associated systemic vasculitis with persistant disease activity. QJM. 2009; 93 (7): 433−439.Atlas po detskoi revmatologii. Pod red. A.A. Baranova, E.I. Alekseevoi [Atlas of Pediatric Rheumatology. Edited by A.A. Baranov, E.I. Alexeeva]. Moscow, Pediatr"", 2009. 248 p.Atlas po detskoi revmatologii. Pod red. A.A. Baranova, E.I. Alekseevoi [Atlas of Pediatric Rheumatology. Edited by A.A. Baranov, E.I. Alexeeva]. Moscow, Pediatr"", 2009. 248 p.Silverman E. D., Cawkwell G. D., Lovell D. G. et al. Intravenous immunoglobulin in the treatment of systemic juvenile rheumatoid arthritis: a randomisrd placebo controlled trial. J. Rheumatol. 1994; 21 (120): 2353–2358.Silverman E.D., Cawkwell G.D., Lovell D.G. et al. Intravenous immunoglobulin in the treatment of systemic juvenile rheumatoid arthritis: a randomisrd placebo controlled trial. J. Rheumatol. 1994; 21 (120): 2353−2358.Gianini E. N., Lovell D. S. et al. Intravenous immunoglobulin in the treatment of polyarticular juvenile rheumatoid arthritis. A phase I/II stady. J. Rheumatol. 1996; 23: 919–924.Gianini E.N., Lovell D.S. et al. Intravenous immunoglobulin in the treatment of polyarticular juvenile rheumatoid arthritis. A phase I/II stady. J. Rheumatol. 1996; 23: 919−924.Permal S., Wechsler B., Cabane J. et al. Treatment of Stills deseas in adults with intravenous immunoglobuline. Rev. Med. Interne. 1995; 16 (4): 250–254.Permal S., Wechsler B., Cabane J. et al. Treatment of Stills deseas in adults with intravenous immunoglobuline. Rev. Med. Interne.1995; 16 (4): 250−254.Prieur S., Wechsler B., Debre V. et al. High dose immunoglobulin therapy in serve juvenile chronic arthritis: longterm follow up in 16 patients. Clin. Exp. Rheumatol. 1990; 8 (6): 603–608.Prieur S., Wechsler B., Debre V. et al. High dose immunoglobulin therapy in serve juvenile chronic arthritis: longterm follow up in 16 patients. Clin. Exp. Rheumatol. 1990; 8 (6): 603−608.Vaitla P. M., McDermott E. M. The role of high-dose intravenous immunoglobuline in rheumatology. Rheumatology (Oxford). 2010; 49 (6): 1040–1048.Vaitla P.M., McDermott E.M. The role of high-dose intravenous immunoglobuline in rheumatology. Rheumatology (Oxford). 2010; 49 (6): 1040−1048.Opperman J., Mobius D. Therapeutical and immunological effects of methylprednisolone pulss therapy in comparison with intravenous immunoglobuline treatment in patients with juvenile chronic arthritis. Acta Universitis Caroline Medica. 1994; 40 (1–4): 117–121.Opperman J., Mobius D. Therapeutical and immunological effects of methylprednisolone pulss therapy in comparison with intravenous immunoglobuline treatment in patients with juvenile chronic arthritis. Acta Universitis Caroline Medica. 1994; 40 (1−4): 117−121.Valieva S.I., Alexeeva E.I., Akulova S.S. et al. Efficacy and safety of prolonged use of rituximab in patients with systemic juvenile idiopathic arthritis. Voprosy sovremennoi pediatrii = Current pediatrics. 2013;12(2):89–100.Valieva S.I., Alekseeva E.I., Akulova S.S. et al. Efficacy and safety of prolonged use of rituximab in patients with systemic juvenile idiopathic arthritis. Voprosy sovremennoi pediatrii = Current pediatrics. 2013; 12 (2): 89–100.Maschan M.A., Poltavets N.V. Hemophagocytic syndrome in pediatric emergency. Pediatricheskaya farmakologiya = Pediatric pharmacology. 2011;8(2):15−21.Maschan M.A., Poltavets N.V. Hemophagocytic syndrome in pediatric emergency. Pediatricheskaya farmakologiya = Pediatric pharmacology. 2011; 8 (2): 15−21.Rosario С. et al. The Hyperferritinemic Syndrome: macrophage activation syndrome, Still’s disease, septic shock and catastrophic antiphospholipid syndrome. BMC Medicine. 2013, 11: 185.Rosário С. et al. The Hyperferritinemic Syndrome: macrophage activation syndrome, Still’s disease, septic shock and catastrophic antiphospholipid syndrome. BMC Medicine. 2013, 11: 185.Lang B. A. et al. Treatment of dermatomyositis with intravenous gammaglobulin. Am. J. Med. 1991; 8: 169–182.Lang B.A. et al. Treatment of dermatomyositis with intravenous gammaglobulin. Am. J. Med. 1991; 8: 169−182.Wedderburn L. R., Rider L. G. Best Pract. Res. Clin. Rheumatol. 2009; 23: 655–678.Wedderburn L.R., Rider L.G. Best Pract. Res. Clin. Rheumatol. 2009; 23: 655−678.Al-Mayouf S. M., Laxer R. M., Schneider R. et al. Intravenous immunoglobulin therapy for juvenile dermatomyositis: efficacy and safety. J. Rheumatol. 2000; 27 (10): 2498–2503.Al-Mayouf S.M., Laxer R.M., Schneider R. et al. Intravenous immunoglobulin therapy for juvenile dermatomyositis: efficacy and safety. J. Rheumatol. 2000; 27 (10): 2498–2503.Deborah M. Levy et al. Favorable Outcome of Juvenile Dermatomyositis Treated Without Systemic Corticosteroids. J. Pediatr. 2010; 156 (2): 302–307.Deborah M. Levy et al. Favorable Outcome of Juvenile Dermatomyositis Treated Without Systemic Corticosteroids. J. Pediatr. 2010; 156 (2): 302–307.Vaitla P. M., McDermott E. M. The role of high-dose intravenous immunoglobuline in rheumatology. Rheumatology (Oxford). 2010; 49 (6): 1040–1048.Vaitla P.M., McDermott E.M. The role of high-dose intravenous immunoglobuline in rheumatology. Rheumatology (Oxford). 2010; 49 (6): 1040−1048.Gokce M., Bilginer Y., Besbas N. et al. Hematological features of pediatric systemic lupus erythematosus: suggesting management strategies in children. Lupus. 2012; 21: 878–888.Gokce M., Bilginer Y., Besbas N. et al. Hematological features of pediatric systemic lupus erythematosus: suggesting management strategies in children. Lupus. 2012; 21: 878–888.Chetan G., Mahadevan S., Sulanthung K., Narayana P. Intravenous Immunoglobulin Therapy of Lupus Pneumonitis. Indian J. Pediatrics. 2007; 74 (11): 1032–1033.Chetan G., Mahadevan S., Sulanthung K., Narayana P. Intravenous Immunoglobulin Therapy of Lupus Pneumonitis. Indian J. Pediatrics. 2007; 74 (11): 1032−1033.Suri V., Varma S., Joshi K. et al. Lupus myocarditis: marked improvement in cardiac function after intravenous immunoglobulin therapy. Rheumatol. Int. 2010; 30: 1503–1505.Suri V., Varma S., Joshi K. et al. Lupus myocarditis: marked improvement in cardiac function after intravenous immunoglobulin therapy. Rheumatol. Int. 2010; 30: 1503–1505.Boletis J. N., Ioannidis J. R., Boki K. A. et al. Intravenous immuno-globulin compared with cyclophosphamide for proliferative lupus nephritis. Lancet. 1999; 354 (9178): 569–570.Boletis J.N., Ioannidis J.R., Boki K.A. et al. Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis. Lancet. 1999; 354 (9178): 569−570.Bucciarelli S., Espinosa G., Cervera R. et al. Mortality in the Catastrophic Antiphospholipid Syndrome. Causes of Death and Prognostic Factors in Series of 250 Patients. Arthritis Rheum. 2006; 54 (8): 2568–2576.Bucciarelli S., Espinosa G., Cervera R. et al. Mortality in the Catastrophic Antiphospholipid Syndrome. Causes of Death and Prognostic Factors in Series of 250 Patients. Arthritis Rheum. 2006; 54 (8): 2568−2576.Caccavo D., Vaccaro F., Ferry G. M. et al. Antiidiotypes against antiphospholipid antibodies are present in normal polyspecific immunoglobulins for therapeutic use. J. Autoimmun. 1994; 21 (12): 2353–2358.Caccavo D., Vaccaro F., Ferry G.M. et al. Antiidiotypes against antiphospholipid antibodies are present in normal polyspecific immunoglobulins for therapeutic use. J. Autoimmun. 1994; 21 (12): 2353−2358.Tenti S., Guidelli G. M., Bellisai F., Galeazzi M. et al. Long-term treatment of antiphospholipid syndrome with intravenous immunoglobulin in addition to conventional therapy. Clin. Exp. Rheumatol. 2013; 1–6.Tenti S., Guidelli G.M., Bellisai F., Galeazzi M. et al. Long-term treatment of antiphospholipid syndrome with intravenous immunoglobulin in addition to conventional therapy. Clin. Exp. Rheumatol. 2013; 1−6.Furusho K., Sato K., Soeda T. et al. High-dose intravenous gammaglobulinfor Kawasaki diseas. Lancet. 1983; 2 (8363): 1359.Furusho K., Sato K., Soeda T. et al. High-dose intravenous gammaglobulinfor Kawasaki diseas. Lancet. 1983; 2 (8363): 1359.Oates-Whitehead R. M., Baumer J. N. et al. Intravenous immunoglobuline for the treatment of Kawasaki diseas in children. Cochrane Database Syst. Rev. 2003; 4: CD004000.Oates-Whitehead R.M., Baumer J.N. et al. Intravenous immunoglobuline for the treatment of Kawasaki diseas in children. Cochrane Database Syst. Rev. 2003; 4: CD004000.Eleftheriou D. et al. Management of Kawasaki disease. Arch. Dis. Child. 2014; 99: 74–83.Eleftheriou D. et al. Management of Kawasaki disease. Arch. Dis. Child. 2014; 99: 74–83.Boman S., Ballen J. L., Seggev J. S. et al. Dramatic responses to intravenous immunoglobulin in vasculitis. J. Int. Med. 1995; 238 (4): 375–377.Boman S., Ballen J.L., Seggev J.S. et al. Dramatic responses to intravenous immunoglobulin in vasculitis. J. Int. Med. 1995; 238 (4): 375−377.Jayne D. R., Lockwood C. M., Fox J. L. et al. Intravenous immuno-globulin as sole for the systemic vasculitis. Brit. J. Rheumatol. 1996; 35 (11): 1150–1153.Jayne D.R., Lockwood C.M., Fox J.L. et al. Intravenous immunoglobulin as sole for the systemic vasculitis. Brit. J. Rheumatol. 1996; 35 (11): 1150−1153.Jayne D. R., Chapel H., Adu D. et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistant disease activity. QJM. 2009; 93 (7): 433–439.Jayne D.R., Chapel H., Adu D. et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistant disease activity. QJM. 2009; 93 (7): 433−439.Pamela F. Weiss. Pediatric Vasculitis. Pediatr. Clin. North Am. 2012; 59 (2): 407–423.Pamela F. Weiss. Pediatric Vasculitis. Pediatr. Clin. North Am. 2012; 59 (2): 407–423.Toussaint S., Geriach H. Immunoglobulins in Adult Sepsis and Septic Shock. Curr. Infect. Dis. Rep. 2012; 14 (5): 522–529.Toussaint S., Geriach H. Immunoglobulins in Adult Sepsis and Septic Shock. Curr. Infect. Dis. Rep. 2012; 14 (5): 522–529.Duhem C., Dicato M., Ries F. Side effects of intravenous immunоglobulins. Clin. Exp. Immunol. 1994; 97 (Suppl. I): 79–83.Duhem C., Dicato M., Ries F. Side effects of intravenous immunоglobulins. Clin. Exp. Immunol. 1994; 97 (Suppl. I): 79−83.Ryan M., Webster M., Statler J. Adverse effects of intravenous immunoglobulin therapy. Clin. Pediatr. 1996; 35: 23–31.Ryan M., Webster M., Statler J. Adverse effects of intravenous immunoglobulin therapy. Clin. Pediatr. 1996; 35: 23−31.Strangel M., Hartung H., Marx P., Gold R. Side effects of high dose intra venous immunoglobulins. Clin. Neuropharmacol. 1997; 20: 385–393.Strangel M., Hartung H., Marx P., Gold R. Side effects of high dose intravenous immunoglobulins. Clin. Neuropharmacol. 1997; 20: 385−393.Burks A., Sampson H., Buckley R. Anaphylactic reactions after gammaglobulin administration in patients with hypogammaglobulinemia. Detection of IgE antibodies to IgA. N. Engl. J. Med. 1986; 314: 560–563.Burks A., Sampson H., Buckley R. Anaphylactic reactions after gammaglobulin administration in patients with hypogammaglobulinemia. Detection of IgE antibodies to IgA. N. Engl. J. Med. 1986; 314: 560−563.Orbach H. et al. Intravenous Immunoglobulin Adverse Effects and Safe Administratio. Clin. Rev. Allergy Immunol. 2005; 29: 173–184.Orbach H. et al. Intravenous Immunoglobulin Adverse Effects and Safe Administratio. Clin. Rev. Allergy Immunol. 2005; 29: 173−184.

The authors declare that there are no conflicts of interest present.